# Acceptability and Feasibility of Injectable Cabotegravir Pre-exposure Prophylaxis (PrEP) Versus Oral PrEP in Routine Care up to 15 Months in Private Pharmacies in South Africa

> **NCT06138600** · PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **University of Witwatersrand, South Africa** · enrollment: 200 (estimated)

## Conditions studied

- HIV Infections

## Interventions

- **DRUG:** Cabotegravir Injection [Apretude]
- **DRUG:** Tenofovir disoproxil fumarate / emtricitabine (or lamivudine)

## Key facts

- **NCT ID:** NCT06138600
- **Lead sponsor:** University of Witwatersrand, South Africa
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2023-11-01
- **Primary completion:** 2025-10-31
- **Final completion:** 2026-01-31
- **Target enrollment:** 200 (ESTIMATED)
- **Last updated:** 2024-06-21

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06138600

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06138600, "Acceptability and Feasibility of Injectable Cabotegravir Pre-exposure Prophylaxis (PrEP) Versus Oral PrEP in Routine Care up to 15 Months in Private Pharmacies in South Africa". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT06138600. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*